INTRODUCTION: To evaluate, the clinical outcomes in patients undergoing cataract surgery with use of sodium hyaluronate 1.4% for its ability to maintain anterior chamber space and protection of corneal endothelial cells.
METHODS: This was a single center, retrospective observational study. A total 52 patients (eyes) having age older than 45 years with Grade I to III cataract were enrolled in the study and BIO-HYALUR Plus was used as ophthalmic viscosurgical device (OVD) during the standard cataract surgery procedure. Pre-operative and post-operative day 1, 1 week, 1 month, and 3 months visits, data assessments included: Adverse events observed during the study were also noted for the evaluation of safety.
RESULTS: Intraoperative anterior chamber space maintenance has been well formed for all 52 (100%) patients (eyes). Corneal clarity was observed for all patients. At 3-month follow-up visit, the mean best-corrected visual acuity was improved to 0.9±0.17 (Snellen Decimal). There was decreased in mean ECC, cell density, intraocular pressure, corneal thickness, coefficient of variance in cell size, and cell area compare to pre-operative visits on follow-up period. No adverse events were reported during entire study
DISCUSSION AND CONCLUSION: BIO-HYALUR Plus OVD cohesive properties and was safe and effective for every stage of cataract surgery without additional toxicity nor result in increased endothelial cell loss.